4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke

Chih Hung Chen, Hock Liew Eng, Chih Jen Chang, Tzu Tung Tsai, Ming Liang Lai, Hsiao Yen Chen, Chien Ju Liu, Tsun Mei Lin

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


The 4G allele of common 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with increased PAI-1 transcription and has been proposed as a candidate genetic risk factor for thrombotic diseases. We investigated the relationship between this polymorphism and lipid profiles and stroke risk. One hundred patients with ischemic stroke and 150 age- and sex-matched control subjects were enrolled. PAI-1 genotype was determined with the use of polymerase chain reaction and restriction-length analysis. Genotype distribution in the stroke group was 40% 4G/4G, 46% 4G/5G, and 14% 5G/5G; in the control group it was 38.7% 4G/4G, 45.3% 4G/5G, and 16% 5G/5G. The allele and genotype frequencies of 4G/5G polymorphism were not different between the stroke and control groups. Control subjects who were homozygous for the 4G allele had significantly lower high-density lipoprotein (HDL) cholesterol levels than did those carrying the 5G allele (51. 2 ± 11.8 vs 58.4 ± 15.8 mg/dL; P = .002). In the control group, regression analysis revealed a significant contribution of 4G/4G genotype to increased triglyceride (P = .042) and to decreased HDL cholesterol (P < .001) levels. Our findings suggest that PAI-1 4G/5G promoter polymorphism alone is not associated with ischemic stroke. However, this polymorphism influences lipid levels, and the underlying mechanism must be determined.

Original languageEnglish
Pages (from-to)100-105
Number of pages6
JournalJournal of Laboratory and Clinical Medicine
Issue number2
Publication statusPublished - 2003 Aug 1

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine


Dive into the research topics of '4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke'. Together they form a unique fingerprint.

Cite this